Skip to main content

21-02-2022 | ASCO GU 2022 | Conference coverage | Video

Potential of sacituzumab govitecan plus pembrolizumab demonstrated in mUC patients

share
SHARE

Petros Grivas explains why sacituzumab govitecan plus pembrolizumab – investigated in cohort 3 of the TROPHY-U-01 study comprising metastatic urothelial cancer patients with progression after platinum-based treatment – is not ready for prime time, but merits further investigation in this setting (5:08).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany